Skip to main content

Advertisement

Table 4 Top 5 most frequent regimens during first-, second-, and third-line therapy

From: Treatment patterns and survival among older adults in the United States with advanced soft-tissue sarcomas

First-line therapy n (%) Second-line therapy n (%) Third-line therapy n (%)
All patients (N = 1227) All patients (N = 476) All patients (N = 189)
Docetaxel–gemcitabine 325 (26.5) Doxorubicin 101 (21.2) Doxorubicin 28 (14.8)
Doxorubicin 231 (18.8) Docetaxel–gemcitabine 83 (17.4) Docetaxel–gemcitabine 21 (11.1)
Gemcitabine 112 (9.1) Gemcitabine 41 (8.6) Gemcitabine 21 (11.1)
Paclitaxel 68 (5.5) Paclitaxel 21 (4.4) Ifosfamide 15 (7.9)
Bevacizumab 41 (3.3) Ifosfamide 20 (4.2) Dacarbazine
Leiomyosarcomas (N = 341)   Leiomyosarcomas (N = 148)   Leiomyosarcomas (N = 66)  
Docetaxel–gemcitabine 136 (39.9) Doxorubicin 41 (27.7) Doxorubicin 12 (18.2)
Doxorubicin 64 (18.8) Docetaxel–gemcitabine 35 (23.7) Docetaxel–gemcitabine
Gemcitabine 43 (12.6) Gemcitabine Gemcitabine
Carboplatin-paclitaxel Docetaxel Carboplatin-paclitaxel
Dacarbazine-doxorubicin Dacarbazine Ifosfamide
Doxorubicin–ifosfamide     
Temozolomide     
Undifferentiated pleomorphic sarcoma (N = 158)   Undifferentiated pleomorphic sarcoma (N = 64)   Undifferentiated pleomorphic sarcoma (N = 24)  
Docetaxel–gemcitabine 36 (22.8) Docetaxel–gemcitabine 1 3 (20.3) Doxorubicin
Doxorubicin 32 (20.3) Doxorubicin Docetaxel–gemcitabine
Gemcitabine 13 (8.2) Ifosfamide Dacarbazine
Ifosfamide 11 (7.0) Gemcitabine Ifosfamide
Doxorubicin–ifosfamide Paclitaxel   
   Temozolomide   
Liposarcomas (N = 140)   Liposarcomas (N = 45)   Liposarcomas (N = 15)  
Doxorubicin 34 (24.3) Docetaxel–gemcitabine 11 (24.4) Ifosfamide
Docetaxel–gemcitabine 31 (22.1) Doxorubicin Gemcitabine
Bevacizumab 13 (9.3) Gemcitabine   
Gemcitabine 12 (8.6) Docetaxel-doxorubicin-gemcitabine   
Doxorubicin–ifosfamide Ifosfamide   
Ifosfamide     
Vascular sarcomas (N = 130)   Vascular sarcomas (N = 60)   Vascular sarcomas (N = 21)  
Paclitaxel 52 (40.0) Doxorubicin 18 (30.0) Doxorubicin
Doxorubicin 22 (16.9) Paclitaxel Doxorubicin–ifosfamide
Docetaxel–gemcitabine Docetaxel–gemcitabine Docetaxel
Doxorubicin–ifosfamide Gemcitabine Docetaxel–gemcitabine
Docetaxel Docetaxel Paclitaxel
Fibroblastic/Myofibroblastic sarcomas (N = 58)   Fibroblastic/Myofibroblastic sarcomas (N = 19)   Fibroblastic/Myofibroblastic sarcomas (N = –)  
Docetaxel–gemcitabine 16 (27.6) Bevacizumab Docetaxel–gemcitabine
Doxorubicin Docetaxel–gemcitabine Gemcitabine
Bevacizumab Bevacizumab-temozolomide   
Gemcitabine Gemcitabine   
Cisplatin Temozolomide   
Doxorubicin–ifosfamide     
Nerve sheath sarcomas (N = 24)   Nerve sheath sarcomas (N = –)   Nerve sheath sarcomas (N = –)  
Doxorubicin Doxorubicin   
Docetaxel–gemcitabine     
Gemcitabine     
Doxorubicin–ifosfamide     
Ifosfamide     
Rhabdomyosarcomas (N = 28)   Rhabdomyosarcomas (N = 15)   Rhabdomyosarcomas (N = –)  
Docetaxel–gemcitabine Doxorubicin   
Carboplatin-paclitaxel Cyclophosphamide-doxorubicin-vincristine   
Cyclophosphamide-dactinomycin-vincristine     
Cyclophosphamide-doxorubicin     
Cyclophosphamide-doxorubicin-vincristine     
Doxorubicin     
Synovial sarcomas (N = 21)   Synovial sarcomas (N = –)   Synovial sarcomas (N = –)  
Docetaxel–gemcitabine Dacarbazine   
Doxorubicin Doxorubicin   
Temozolomide Ifosfamide   
Others/NOS (N = 327)   Others/NOS (N = 109)   Others/NOS (N = 46)  
Docetaxel–gemcitabine 81 (24.8) Docetaxel–gemcitabine 14 (12.8) Gemcitabine
Doxorubicin 61 (18.7) Doxorubicin 14 (12.8) Ifosfamide
Gemcitabine 30 (9.2) Gemcitabine 12 (11.0) Dacarbazine
Carboplatin-paclitaxel 16 (4.9) Carboplatin-paclitaxel Docetaxel–gemcitabine
Paclitaxel 12 (3.7) Docetaxel Doxorubicin
   Doxorubicin–ifosfamide   
   Ifosfamide   
  1. Only showing treatment regimens received by more than 1 patient
  2. NOS not otherwise specified